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Abstract
Background: Our previous studies of Alzheimer’s disease (AD) suggested that glutamine broadly improves cellular
readiness to respond to stress and acts as a neuroprotectant both in vitro and in AD mouse models. We now
expand our studies to a second neurodegenerative disease, ataxia-telangiectasia (A-T). Unlike AD, where clinically
significant cognitive decline does not typically occur before age 65, A-T symptoms appear in early childhood and
are caused exclusively by mutations in the ATM (A-T mutated) gene.
Results: Genetically ATM-deficient mice and wild type littermates were maintained with or without 4 % glutamine
in their drinking water for several weeks. In ATM mutants, glutamine supplementation restored serum glutamine
and glucose levels and reduced body weight loss. Lost neurophysiological function assessed through the
magnitude of hippocampal long term potentiation was significantly restored. Glutamine supplemented mice
also showed reduced thymus pathology and, remarkably, a full one-third extension of lifespan. In vitro assays
revealed that ATM-deficient cells are more sensitive to glutamine deprivation, while supra-molar glutamine
(8 mM) partially rescued the reduction of BDNF expression and HDAC4 nuclear translocation of genetically
mutant Atm−/− neurons. Analysis of microarray data suggested that glutamine metabolism is significantly
altered in human A-T brains as well.
Conclusion: Glutamine is a powerful part of an organism’s internal environment. Changes in its concentrations can
have a huge impact on the function of all organ systems, especially the brain. Glutamine supplementation thus bears
consideration as a therapeutic strategy for the treatment of human A-T and perhaps other neurodegenerative diseases.
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Background
Glutamine (Gln or Q) is the most abundant free amino
acid in the human blood stream. Normally, the body can
make enough glutamine for its needs and under these
conditions glutamine is a non-essential amino acid. Yet
in times of stress glutamine is depleted from the blood
stream faster than it can be produced in muscle and
other tissues. Under these conditions, cells become
dependent on an exogenous supply of glutamine. This
context-dependent shift has led to the classification of
glutamine as a “conditionally essential” amino acid. In the
central nervous system, brain glutamine is the major sub-
strate for the generation of both excitatory and inhibitory
neurotransmitters (glutamate and γ-aminobutyric acid). It
is also a vital source of energy for the nervous system as it
feeds directly into the tricarboxylic acid (TCA) cycle, the
main source of ATP in the cell.
We have previously shown the neuroprotective
value of glutamine supplementation in vitro and in
vivo [1]. Specifically, short term oral glutamine sup-
plementation significantly reduces the biochemical in-
dices of neurodegeneration in mouse models of
Alzheimer’s disease. The benefits of glutamine supple-
mentation were broad spectrum and included
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reduction of tau phosphorylation, blockage of neur-
onal cell cycle reentry, improvement in the DNA
damage response and a reduction in synaptic protein
loss. As part of this earlier study we showed that low
glutamine decreases the abundance of several key
stress response proteins, including ATM (ataxia-tel-
angiectasia mutated).
ATM deficiency, caused by mutations in the ATM
gene, underlies a childhood neurodegenerative disease
known as ataxia telangiectasia (A-T). Due to the loss of
cerebellar Purkinje and granule cells, patients with A-T
suffer from uncoordinated or ataxic movements begin-
ning at 2–3 years of age [2]. A-T patients also have
increased mortality because of cancer, respiratory system
infections, and various other rare complications. The
median life-span of an individual with A-T is about
23 years [3]. Affected individuals can also develop car-
diovascular disease, accelerated aging, and insulin resist-
ance. Systemic inflammation may contribute to these
disease phenotypes as an immune challenge significantly
alters the timing and severity of the A-T phenotype in
Atm−/− mouse brain [4, 5]. Although there are no reports
of an inflammatory reaction in their brains, A-T patients
have elevated serum IL8, a pro-inflammatory CXC che-
mokine and neutrophil chemoattractant associated with
premature cellular senescence and chronic inflammatory
disorders [6]. Notably, recent studies have suggested that
glutamine plays an important role in regulating IL8 secre-
tion; deprivation of glutamine stimulates IL8 secretion in
U2OS osteosarcoma cells and A549 lung cancer cells as
well as in human A-T fibroblasts [7, 8].
Beyond these immune system abnormalities, A-T chil-
dren are known to have a lower body mass index and
often fail to thrive [9–11]. A recent study by Ross et al.
demonstrated profound malnutrition in A-T patients
and the need for early nutritional intervention [12].
These observations plus the neuroprotective effect seen
in mouse models of Alzheimer’s disease led us to
hypothesize that glutamine might be beneficial in A-T as
well as in AD. In this study, we present multiple lines of
evidence from Atm−/− mice in support of this hypoth-
esis. We suggest that glutamine supplementation has
significant potential as part of a therapeutic regimen for
the treatment of A-T.
Methods
A-T mouse models
For our A-T model, we chose the Atmtm1Awb mutant
allele [13] and the Atmtm1Bal mutant allele [14] from
The Jackson Laboratories. All in vivo experiments were
done using Atmtm1Awb strand. For primary neuron cul-
ture, both strands were used. All animal procedures
were performed according to Rutgers University Institu-
tional Animal Care and Use Committee standards.
Glutamine supplement
For glutamine supplementation experiments, 4 % glu-
tamine (Sigma) in sterile tap water was made fresh daily
and offered as the sole source of drinking water for 5
consecutive days (Monday through Friday). Control mice
were fed with only sterile tap water. To avoid undue
stress from elevated ammonia concentrations, all mice
drank glutamine-free water 2 days each week (Saturday
and Sunday).
Blood glucose and glutamine measurements
About 0.3 ml blood was collected by quick sub-
mandibular bleeding from mice before sacrifice. Non-
fasting blood glucose concentration was measured using
the Roche Accu-Chek Aviva Plus Blood Glucose Meter.
For glutamine assays, blood samples were deproteinized
immediately using the Deproteinizing Sample Prepar-
ation Kit from BioVision following the manufacture’s
protocol. Deproteinized samples were kept in the −80°
freezer before assay. Blood glutamine concentration was
measured using EnzyChrom™ Glutamine Assay Kit from
BioAssay Systems following the manufacturer’s protocol.
Primary neuronal cell cultures
Timed pregnancies were established from wild type ICR
mice (Taconic Biosciences) or wild type mice from Atm−/−
colonies. Embryos were harvested on embryonic day
15.5–16.5 for cortical neuron culture as previously de-
scribed [15]. Neurons were cultured in normal medium
with 2 mM of a glutamine-alanine dipeptide (GIBCO®
GlutaMAX™, Life Technologies) as a source of glutamine.
Culture media were changed every 4–5 days. On DIV9–
11, neurons were fed with fresh medium with different
concentrations of Glutamax. 72 h later, on DIV12–14,
neurons were collected for immunostaining or western
blotting or gene expression analysis. To block endogenous
glutamine production, neurons were treated with a com-
bination of 5 mM glutamine synthase (GS) inhibitor
methionine sulfoximine (MSO) (Sigma). Either ATM-
specific inhibitor Ku55933 (10 μM) or Ku60019 (2 μM)
(Calbiochem, currently Merck Millipore) was used to in-
hibit ATM activity in wild type neurons. shRNA against
Atm was used to study the effect of gene knockdown.
shRNA against mouse ATM [pGFP-C-shLenti-ATM
(TL500154), OriGene] were transfected with Lipofecta-
mine LTX (Life Technologies). Six hours after transfec-
tion, cells were refreshed with culture medium and
further incubated for 48 h for gene knockdown prior to
being challenged at different glutamine concentrations for
another 72 h.
Western blots and immunocytochemistry
For western blot analysis, cultured neurons were lysed in
RIPA buffer (Thermo Scientific) containing proteinase
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and phosphatase inhibitors (Roche Diagnostics). Equal
amounts of protein were separated on 4–20 % SDS
PAGE gradient gels (Bio-Rad) and then transferred to
PVDF or nitrocellulose membranes (Bio-Rad) for
immunodetection. Primary antibodies used were:
ATM2c1 and 53BP1 (Abcam); Actin (Santa Cruz Bio-
technology); GFAP, GS, mTOR and P-mTORs2448
(Cell Signaling); and tau3R (Millipore). Secondary
antibodies were chicken anti-rabbit IgG-HRP and
chicken anti-mouse IgG-HRP (Santa Cruz Biotechnol-
ogy). Chemiluminescent substrates used were Super-
Signal™ West Pico Chemiluminescent Substrate and
SuperSignal™ West Femto Maximum Sensitivity Sub-
strate (Thermo Scientific). For immunofluorescence
staining, neurons were fixed in 4 % paraformaldehyde
for 30 min. Fixed cells were then incubated in block-
ing buffer (10 % goat serum, 0.5 % Triton X100 in
PBS) for 1 h. Primary antibody HDAC4 (1:1000,
Abcam) incubation were carried out in 4°, overnight.
Alexa linked secondary antibodies (Life Technologies)
were used to detect the presence of the HDAC4 anti-
gens. Stained cells were photographed and viewed at
a final magnification of 200 using Leica Application
Suite/Leica DM5000B.
RT PCR and real-time PCR
Total RNA was purified using TRIzol reagent (Life
Technologies) following the standard protocol. For real-
time PCR, cDNAs were generated from total RNA using
High Capacity cDNA Reverse Transcription Kit (ABI).
The PCR reactions were done using iTaq Universal
SYBR Green Supermix (Bio-RAD) on an ABI PRISM®
7900HT Sequence Detection System. Primer sets used




For mBDNF (common region)
Forward: gaaggctgcaggggcatagacaaa
Reverse: tacacaggaagtgtctatccttatg.
Because PCR products for BDNF exons 2, 3 and 4
were larger than optimal for real-time PCR analysis,
expressions of these exons were analyzed by RT-PCR
using the SuperScript® III One-Step RT-PCR System
with Platinum® Taq DNA Polymerase kit (Life Tech-
nologies) on a Techne PrimeG gradient enabled ther-
mal cycler. PCR products were resolved in 1.5 %
agarose gel and visualized by staining with ethidium
bromide. Relative expression concentrations were de-















Extracellular recordings of field EPSPs (fEPSPs) were
made with ACSF-filled glass electrodes (5–10 μm tip
diameter) according to protocols previously established
in our lab [16]. For baseline recordings, test stimuli
(0.1 ms) were delivered with a bipolar platinum/iridium
stimulating electrode at 1 min intervals. For recordings
of CA1 activation by Schaffer collateral stimulation, re-
cording and stimulating electrodes were both placed in
stratum radiatum. Each experiment was begun by
obtaining input–output relationships to establish the
strength of baseline synaptic transmission. A Grass
S8800 stimulator connected to a Grass PSIU6 photo-
electric stimulus isolation unit was used to deliver a
series of increasing intensity constant current pulses.
Current magnitude is adjusted to elicit responses ran-
ging from just-suprathreshold to near maximal. Fol-
lowing this, stimulus intensity was adjusted to evoke
fEPSPs 30–40 % of maximum, typically 30–40 μA. To
elicit long-term potentiation (LTP), theta burst stimu-
lation (TBS) was used. A single stimulus consists of
6–12 bursts of four 100 Hz pulses spaced 200 ms
apart. Response magnitude was quantified using the
slope of the field potential.
Microarray data
Human A-T and mouse Atm−/− gene expression datasets
were published previously [17] and are available from
the NIH GEO archive under accession numbers
GSE50951 and GSE61019.
Statistics
For lifespan study, the significance of the difference
between the glutamine and control curves was deter-
mined by the Mantel-Cox log-rank test. For the rest of
the studies, the p values were determined by Student t-
test. *** denotes p < 0.001; ** denotes p < 0.01; * denotes
p < 0.05; n.s. means p ≥ 0.05.
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Results
Glutamine modulates the metabolomics of ATM
deficiency
Our previous research has shown that glutamine has
a broad neuroprotective effect [1], so we became in-
terested in whether glutamine deficiency contributed
to the A-T phenotype. As such, we first asked
whether Atmtm1Awb/tm1Awb mice (referred to as Atm−/−
or AWB) presented with any evidence of glutamine
deficiency. Blood glutamine concentrations of Atm−/−
mice were measured (see Methods) and found to be
25 % below those in age-matched control mice (Fig. 1,
p < 0.001). Feeding glutamine for 2-weeks did not
change the glutamine concentration in wild type mice
(p = 0.5); however, glutamine supplementation signifi-
cantly increased the concentration of blood glutamine
in Atm−/− mice (p < 0.02), raising it to levels compar-
able to wild type. These observations suggest first that
blood glutamine concentration is tightly regulated in
the wild type as extra glutamine has little effect and
second that the Atm−/− mouse is intrinsically glutam-
ine deficient, thus explaining why glutamine supple-
mentation helps to restore normal serum levels.
Glutamine is believed to be important for maintaining
euglycemia by modulating secretion of glucagon-like
peptide 1 (GLP-1) [18–20]. As ATM deficiency is already
associated with defective glucose homeostasis and mild
diabetes [21, 22], we predicted that blood glucose con-
centrations would also be reduced in A-T. Thus, we first
measured the non-fasting blood glucose concentrations
of our glutamine treated and untreated animals (Fig. 2).
In wild type mice from our Atm colony, resting blood
glucose concentrations were 136 ± 11 mg/dl. ATM-
deficient littermates had only 122 ± 14 mg/dl blood glu-
cose, a significant reduction (p < 0.01). Thus, as in
humans, ATM deficiency impairs glucose metabolism in
ATM-deficient mice. We next asked whether oral glu-
tamine supplementation might have an impact on this
metabolic imbalance. In wild-type animals, oral glutam-
ine supplementation had no effect on blood glucose
concentrations (p = 0.99). In contrast, in Atm−/− mice,
an 8-week regimen of oral glutamine supplementation
increased blood glucose significantly (p < 0.05), restoring
the values to near wild type levels. Of note, this increase
was observed almost exclusively in the male mice; there
was little difference in the glucose levels of female mice.
The cause for this gender difference has not been ascer-
tained. However, it is still clear that glutamine supple-
mentation can restore proper blood glucose levels when
they are abnormal, yet has no effect on the homeostatic
mechanisms of the wild type animals, a finding of
clinical significance.
Consistent with the metabolic changes observed, we
found that the total body weight of the mice was also
affected by the addition of glutamine to their diet. Once
again, the supplement had no effect on the wild-type
controls; their developmental weight gain was identical
with and without supplementation. Consistent with
Fig. 1 Oral glutamine supplementation increases non-fasting blood
glutamine concentrations in Atm−/− mice. Atm−/− mice (green or blue
symbols) have significantly lower glutamine blood glutamine com-
pared to age-matched wild type mice (purple or red symbols). Glutam-
ine supplementation significantly improves the blood glutamine deficit
of Atm−/− mice but has no effect on wild type mice. Symbols with a
white square inside indicate female mice. Statistically different by
two-tailed t-test: **, p < 0.01; *, p < 0.05; n.s. (not significant)
p ≥ 0.05
Fig. 2 Atm−/− mice have significantly lower blood glucose
concentration compared to their wild type littermate mice.
Glutamine supplementation of the Atm−/− mice significantly increased
their blood glucose concentration. Unlike Atm−/− mice however,
feeding glutamine had no effect on blood glucose of wild type mice.
This effect was sexually dimorphic with a strong effect in males, but no
effect observed in female Atm−/− mice. Symbols with a white circle
inside indicate female mice. Statistically different by two-tailed t-test: **,
p < 0.01; n.s. (not significant) p≥ 0.05
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previous findings, Atm−/− mice of both sexes weigh sig-
nificantly less than their wild-type counterparts at all
ages. Further, in these ATM deficient mice, glutamine
supplementation had a significant effect on their size.
Intriguingly, this effect also showed a strong sexual
dimorphism. In male mice, the supplement enabled the
animals to gain weight much faster than their un-
supplemented littermates (although even 2 months of
supplementation were not enough to allow them to
catch up with the wild-type animals). In female Atm−/−
mice, however, the exact reverse was observed: glu-
tamine supplementation retarded their developmental
weight gain (Fig. 3). This male/female difference in
Atm−/− mice is not seen in un-supplemented animals
and has no known precedent in the A-T clinical literature.
Glutamine supplementation modulates synaptic plasticity
We have shown previously [16] that Atm−/− mice have a
significant deficit in TBS-induced Schaffer collateral LTP
(long term potentiation) as compared to wild-type mice.
To see if glutamine supplementation would be effica-
cious in improving this deficit, we evaluated LTP magni-
tude in homozygous Atm−/− animals with glutamine
treatment. Hippocampal synaptic activity was assessed
with field potential recording of the CA3-CA1 synaptic
pathway. To avoid ceiling effects, LTP was evoked with
trains containing 6 theta bursts (6xTBS), which allows
both increased and decreased response magnitude to be
detected. A cohort of Atm−/− animals that received glu-
tamine supplementation in their diet showed elevated
LTP (153 ± 4.7 % above baseline; Fig. 4a, filled symbols)
as compared to untreated animals from a separate paral-
lel study (127 ± 8.1 % above baseline; Fig. 4a, dotted line)
[23]. The improvement in synaptic strength was limited
to late LTP; the early increases in synaptic strength that
decayed within the first 30 min post-6xTBS did not
differ between treated and untreated animals. To assess
baseline synaptic strength, we also obtained input–out-
put relationships for Atm−/− mice with and without glu-
tamine supplementation (Fig. 4b). The relationship
between stimulus current and slope of the fEPSP was
comparable to wild-type animals and did not differ sig-
nificantly between the two groups of animals (p > 0.3).
This suggests that restoration of LTP by glutamine does
not result from an overall increase in synaptic strength
but rather is limited to an effect on synaptic plasticity.
Glutamine prolongs the lifespan of the ATM−/− mice
The observations of improvement in hippocampal cir-
cuitry (synaptic plasticity), blood glucose, blood glutam-
ine, and body weight gain led us to ask whether these
individual improvements following glutamine supple-
mentation might work together in such a way that there
was an overall impact on the life-span of the mutant
mice. To address this question, we randomly divided a
cohort of 42 Atm−/− mice into two groups. One group
was fed drinking water supplemented with 4 % glu-
tamine; the other group had only normal water to
drink. Normally, in our colony, the average life span
of an Atm−/− mutant mouse is approximately 85 days
(Fig. 5a black symbols). Glutamine supplementation
led to a significant increase in this figure. We began
glutamine treatment at 4–5 weeks of age, and found
that this supplementation increased the lifespan of
ATM-deficient mice by nearly one third to 120 days
(p < 0.0001; Fig. 5a, red symbols). Given that in female
mice glutamine has no effect on blood glucose con-
centration and even leads to lower weight gain, we
Fig. 3 Glutamine supplementation improves the body weight of Atm−/− mice in a gender-specific manner. Male Atm−/− mice gained weight
significantly faster during their 8-week supplementation with glutamine. The rate of weight gain in glutamine-fed female Atm−/− was significantly
slower than female Atm−/− mice on regular drinking water. Symbols: solid lines = control drinking water; dotted lines = glutamine supplementation.
There were 8–10 mice in each of the 8 study groups, and a total of 69 mice were used in the body weight study. Statistically different by two-tailed
t-test: *, p < 0.05. Error bars = standard errors
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were particularly intrigued that this effect on life span
was seen in both males and females. Nonetheless, as
the mutant males in our colony have significantly
shorter lifespans than the mutant females (p < 0.001)
the glutamine effect was more pronounced in males,
a 40-day extension in males compared to a 21-day
extension in females (Fig. 5b).
Atm−/− mice consistently develop thymic lymphoma
early in life, and almost all Atm−/− mice die of these
cancers [24]. During autopsy of the mice in the blood
glutamine study, we noted variability in the extent of
the visible thymic pathology. Recall that there is also
a large variation of blood glutamine concentrations
among Atm−/− mice (Fig. 1). This led us to ask
whether the two phenotypes might be correlated. In-
deed, we found that Atm−/− mice that presented with
visible abnormalities in the thymus at sacrifice (appar-
ently enlarged thymus or visible tumor) had signifi-
cantly lower blood glutamine (0.6 ± 0.09 mM) than
Atm−/− mice with normal thymus (1.0 ± 0.09 mM – p
< 0.01) (Fig. 6). Thus, while there is a generalized re-
duction of blood glutamine levels in Atm−/− animals
(Fig. 6), in the subset of mutants with more normal
levels of glutamine, thymus pathology is significantly
less likely than in those with low blood glutamine
levels. As would be predicted from this observation,
none of the five 10-week old Atm−/− mice fed with
glutamine for 2 weeks presented with abnormal
Fig. 4 LTP in Atm−/− animals can be improved by dietary supplementation with glutamine. a. Plots of fEPSP slope, normalized to baseline,
showing the responses of Atm−/− animals to the 6xTBS induction protocol. After 10 min of baseline recording, the TBS train was delivered at
time = 0. Filled symbols show the average response of animals that received glutamine. Dotted line shows the average response of untreated
Atm−/− animals from a separate parallel study [23]. b. Input–output plot of fEPSP slope in response to single pulses of increasing amplitude.
Stimulus intensities of 10, 20, 40, 60, 80, 100, and 120 μA were tested. There was not a significant difference between Atm−/− animals with and
without glutamine (p > 0.3, t-test, two-sided). Error bars = standard deviations
Fig. 5 Glutamine supplementation significantly increases the life span of Atm−/− mice. a Kaplan-Meyer curves of the mice. Atm−/− mice on normal
diet (control, squares) had a mean lifespan of 85 days (16 females and 7 males); Atm−/− mice with glutamine supplementation (circles) had a
mean lifespan of 120 days (13 females and 6 males). The significance of the difference between the glutamine and control curves was determined
by the Mantel-Cox log-rank test. b Glutamine significantly extends life span of both male and female Atm−/− mice. The mean age at death is plotted
separately for male (M) and female (F) Atm−/− mice either with (Gln) or without (Cont) dietary glutamine supplementation. Statistically different by
two-tailed t-test: ***, p < 0.001; **, p < 0.01. Values represent means and standard errors
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thymus while half of the Atm−/− littermates on regu-
lar drinking water had an abnormally enlarged thy-
mus (Fig. 1, AWB/Glutamine blue symbol vs AWB/
Control green symbol). Taken together, these observa-
tions suggest that glutamine may prolong the lifespan
of Atm−/− mice by slowing tumorigenesis and/or
tumor progression.
Gene expression changes in glutamine metabolism in A-T
brains
The data thus far show that glutamine supplementation
is beneficial in many ways to Atm−/− mice. To determine
whether this finding applied to human individuals with
A-T, we re-analyzed data from our previous gene expres-
sion array studies of tissue from wild type and Atm−/−
mouse cerebellum, as well as tissue from cerebellar cor-
tex of control and A-T patients [17]. Given the dramatic
metabolic changes brought on by ATM deficiency in
mice, we queried this data set to determine if the
systemic changes in the metabolomics profile were
matched in the patterns of gene transcription found in
brain. We focused on genes involved in glutamine
metabolism whose expression was significantly altered in
ATM deficiency [≥1.5 fold increase or decrease, p ≤
0.05]. We found, both in human A-T and Atm−/− mice,
that the expression of glutaminase (GLS) was increased
while the next enzyme in the pathway towards the TCA
cycle, glutamate dehydrogenase (GLUD), was decreased
(Fig. 7). We also found significant downregulation of
several genes involved in glutamine metabolic pathways –
asparagine synthetase (ASNS, glutamine hydrolyzing),
glutamate decarboxylase (GAD), glutathione synthetase
(GSS) and glutamine-fructose-6-phospate-transaminase
(GFPT) and glutamic oxaloacetic (pyruvate) transaminase
(GOT/GPT) – but these changes were only significant in
the human data set. Upregulation of GLS suggests that
Fig. 6 Atm−/− mice with abnormal thymus (enlarged thymus or
visible thymic tumor) have significant lower blood glutamine
concentration compared to Atm−/− mice with normal thymus. Wild
type mice with normal thymus (WT, n = 15, 7 males and 8 females);
Atm−/− mice were divided in to two groups: normal thymus (n = 8,
4 males and 4 females) and abnormal thymus (n = 6, 4 males and 2
females). Statistical significance was calculated using two-tailed t-test:
** = p < 0.01; n.s. (not significant, p > 0.05). Values represent means
and standard errors
Fig. 7 Gene expression analysis of control and ATM-deficient human and mouse brains revealed that ATM deficiency had a huge impact on
genes known to take part in brain glutamine metabolism. Presented are a list of genes whose expressions were found to be significantly reduced
or increased in ATM-deficient human or mouse brains (>1.5 fold change when compared to control brains, p < 0.05). Upregulated genes
are indicated by an black upward arrow next to the gene name; downregulated genes are shown by a downward arrow. Genes whose
direction of change was significant in both mouse and human data are shown with underlines
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ATM-deficient cells rely more on glutamine for energy
production and is consistent with the observed reduction
in serum glutamine in Atm−/− animals. Down regulation
of GLUD, GAD, ASNS, GSS, GFPT and GOT/GPTA in
A-T brains implies a less efficient production of other
molecules important for normal neuronal functions in-
cluding GABA, asparagine, glucosamine, and glutathione.
This may be a contributing factor in pathogenesis of A-T.
Having identified significant changes in individual
gene expression, we then re-queried the entire database
using Ingenuity Pathway Analysis software to help iden-
tify ensembles of genes whose expression was signifi-
cantly changed in A-T brains (≥1.5 fold, p ≤ 0.05).
Upstream Regulator Analysis (URA) identifies molecules
upstream of the genes in the data set that potentially
explain the observed expression changes [25]. Based on
the list of significantly down regulated genes, URA pre-
dicted glutamine to be a likely upstream regulator with
an overlap p value of 0.001 (Fisher’s exact test) and an
activation Z score of 0.03. This suggests that glutamine
target genes are significantly enriched in the group of
genes that are down regulated in A-T. One additional
finding of this analysis that we found particularly
reassuring given our earlier work [4, 5] was that NFkB
and TNF were predicted to be the upstream regulators
for the significantly up-regulated genes, as previous
studies have documented constitutional activation of
NFkB signaling in ATM-deficient cells [26, 27].
Glutamine-deprivation leads to reduced ATM expression
and deregulation of the mTOR pathway
To better understand the interplay between glutamine
metabolism and ATM deficiency, we turned to cell cul-
ture to isolate the individual effects. We have shown that
the concentrations of stress response proteins such as
ATM are reduced when embryonic cortical neurons are
grown in glutamine-free medium [1]. However, glutam-
ine can be synthesized by astrocytes via glutamine
synthetase (GS). Therefore, we added the GS inhibitor
methionine sulfoximine (MSO) to block endogenous
glutamine production (Fig. 8). Removal of either exogen-
ous glutamine (lane 3) or endogenous glutamine with
MSO (lane 2) had little or no effect by themselves.
When we removed glutamine in the medium and added
MSO (depletion of both exogenous and endogenous
glutamine), we observed a dramatic reduction in the
levels of ATM protein (lane 4). Reduced glutamine level
also caused formation of oxidized ATM dimer (black
arrow). Thus, the maintenance of a healthy concentra-
tion of ATM expression depends on an adequate
glutamine supply. The results with a second stress
response protein, 53BP1, were similar. The fact that
neither of these proteins decreases in the presence of
MSO alone means that an adequate supply of exogenous
glutamine can overcome the loss of endogenous glutam-
ine production. This finding validates a benefit from
dietary intervention as a means of manipulating cellular
glutamine concentrations. Endogenous glutamine is
known to directly affect mTOR activity in multiple cell
types [28]. Further, mTOR has an important reciprocal
regulatory relationship with ATM. mTOR can repress
ATM expression [29] while ROS-induced ATM activa-
tion can repress mTOR activity [30]. Together, these
observations suggest the possibility that the effects of
glutamine on ATM expression may be mediated by the
mTOR pathway.
In cultured wild-type mouse neurons, low exogenous
glutamine almost completely suppresses mTOR phos-
phorylation (Fig. 8b, compare lane 4 to lane 1), while
inhibiting endogenous glutamine production increases it
Fig. 8 Glutamine deprivation leads to significant reduction in ATM and mTOR concentrations in neurons. a Both endogenous and exogenous
glutamine are required for stable concentrations of ATM and 53BP1 in neurons. b Glutamine and ATM interact to modulate mTOR concentration
and mTOR activity. The symbols above the lanes indicate the presence (+) or absence (−) of 2 mM Glutamax (gln), 5 mM methionine sulfoximine
(mso), a glutamine synthase inhibitor or 10 μM KU55993 (Ku), an ATM inhibitor
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(compare lane 2 to lane 1). This increase is completely
dependent on exogenous glutamine (compare lane 5
to lane 2), as well as ATM activity (compare lane 2
to lane 3). These observations confirm the relation
between glutamine, ATM and mTOR. Of note is the
fact that the basic cytoarchitecture of the cells, as
measured by the concentrations of the microtubule
associated protein tau, seems largely unaffected by
either ATM or GS inhibition.
ATM-deficient neurons are more dependent on
exogenous glutamine
ATM is required throughout the lifetime of a neuron. It
is the primary mediator of the response to DNA double
strand breaks that arise from exposure to ionizing
radiation. However, cells lacking ATM are also hypersen-
sitive to insults other than double strand breaks, particu-
larly oxidative stress. Since glutamine is essential for
these responses [1], we hypothesized that ATM-deficient
cells in culture would be more dependent on exogenous
glutamine.
Recent studies from our lab have shown that ATM regu-
lates the cytoplasmic location of histone deacetylase 4
(HDAC4) [31]. Because ATM deficiency causes nuclear ac-
cumulation of HDAC4 in neurons and promotes
neurodegeneration, we evaluated cultured Atm −/− and
wild-type neurons’ response to glutamine deficiency by
monitoring HDAC4 localization (Fig. 9). We found that
low glutamine caused a significant increase in the
percentage of neurons with nuclear HDAC4 in both
Fig. 9 Atm−/− neurons are significantly more sensitive to glutamine deficiency. Wild type and Atm−/− primary neurons were grown in culture
media with or without glutamine supplementation for 24 h, and then stained with HDAC4. For quantification, 5 random fields of 200 cells for
each condition were counted
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genotypes (nuclear HDAC4, green bars). However, even
when given glutamine, the localization of HDAC4 in Atm
−/− neurons was still far from normal. Only 10 % of the
Atm−/− neurons maintained an exclusively cytoplasmic
localization of HDAC4 upon removal of glutamine com-
pared to over 60 % in the wild type (Fig. 9, blue bars). Not-
ably, Atm−/− neurons grown in low glutamine have
significantly higher percentage of cells contained nuclear
HDAC4; about two fold increase (Fig. 9, green bars). These
data suggest that ATM-deficient neurons are heavily
dependent on exogenous glutamine supplementation to
maintain their normal epigenetic landscape.
Considering the similarities in nuclear HDAC4 popu-
lations between glutamine-deprived wild-type neurons
and Atm−/− neurons in normal media, we hypothesized
that increased glutamine supplementation would be
beneficial to ATM-deficient cells. To test this idea, we
performed an extensive analysis on the effect of glutam-
ine dosages (0, 2 and 8 mM) on HDAC4 localization. In
DIV14 wildtype Atm+/+ neurons, elimination of glutam-
ine in the culture led to modest HDAC4 nuclear
localization. The presence of glutamine in the culture
medium completely prevented the nuclear presence of
HDAC4 (Fig. 10). In contrast, in models of ATM defi-
ciencies such as neurons isolated from Atm−/− mice,
wildtype neurons treated with ATM specific inhibitor
Ku-66019 and wildtype neurons with endogenous Atm
knocked down with shRNA, removing glutamine from the
culture medium robustly rendered HDAC4 to be localized
in the nucleus. The presence of glutamine prevented such
phenomena, and the effect became more prominent when
glutamine supplementation was high (8 mM). In sum-
mary, glutamine reversed HDAC4 nuclear translocation
(epigenetic changes) resulting from ATM-deficiency
whether due to genetic deficiency (Atm−/−), acute knock-
down (shRNA), or the pharmacological inhibition of en-
zyme activity of ATM (Ku).
To measure the glutamine effect with a more quantita-
tive method, we turned to brain-derived neurotrophic
factor (Bdnf) gene expression. Our previous studies have
shown that Bdnf expression is significantly down regu-
lated in ATM-deficient neurons [31]. Late phase LTP is
known to be dependent on BDNF [32] and, as our
physiological experiments have shown, the effect of glu-
tamine is most prominent at these times suggesting a
linkage (Fig. 4a). To test this idea, cultured wild type
neurons were treated with KU59933 and grown in 0, 2
and 8 mM glutamine. As shown in Fig. 11, neurons
grown in 8 mM glutamine expressed significantly higher
levels of BDNF message (the common exon) than those
grown in 0–2 mM glutamine (Fig. 11a). Transcription of
the mouse Bdnf gene is controlled by more than 9
promoters, resulting in at least 18 transcripts. Interest-
ingly, individual splice variants of the BDNF message
responded differently to glutamine. 8 mM glutamine
increased the expression of exon4 significantly in Ku
treated neurons but had no effect on untreated neurons
(Fig. 11b). Given that exon 4 is critical for GABAergic
transmission and plasticity of frontal cortex [33], these
observations suggest that glutamine may act on LTP
Fig. 10 The effect of glutamine on HDAC4 localization. a DIV14 neurons from Atm wildtype (Atm+/+), or knockout (Atm−/−) were cultured under
various dosages of glutamine for 72 h. To access the role of ATM kinase activity, treatment with 2 μM of ATM specific inhibitor (KU-60019) was
initiated in DIV9 wildtype neurons for 48 h in complete medium, followed by glutamine treatment at different dosage for another 72 h. b shRNA
against Atm was also used to study the effect of losing the protein in mature neurons. shRNA was transfected into DIV9 wildtype neurons for
48 h in complete medium, followed by glutamine treatment at different dosage for another 72 h. Effect on HDAC4 localization was analyzed by
immunohistochemistry. Scale Bar = 25 μm. N = 3
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through restoration of the concentrations of Bdnf in
ATM-deficient neurons.
Discussion
Cultured neurons exposed to exogenous stressors such as
DNA damage, heavy metals, oxidation or the Aβ peptide
have heightened vulnerability to glutamine deprivation [1].
In mouse models of familial Alzheimer’s disease (AD), oral
glutamine supplementation reduces phosphorylated tau as
well as the ectopic appearance of neuronal cell cycle
proteins [1]. We have now extended these AD-related
studies to a second neurodegenerative disease, ataxia-
telangiectasia (A-T). The AD model we tested was the
R1.40 mouse [34]. These animals are a faithful genetic
mimic of early-onset APP-driven dominantly inherited
forms of human familial AD. Ataxia-telangiectasia is a
recessive genetic condition of childhood neurodegenera-
tive disease caused by mutations in the ATM gene. It is a
true multi-systemic disease, but the neurological symp-
toms are the most prevalent and the most debilitating. On
the surface, AD and A-T seem like very differences
diseases, but our research shows that glutamine has a
positive impact on the phenotype of both. This may be
mediated through ATM, as we have recently discovered
that AD patients often exhibit ATM deficiency, as seen
through HDAC4 nuclear translocation in hippocampal
neurons [35]. Our finding on the powerful neuropro-
tective effects of glutamine in mouse models in both
AD and A-T suggests that its benefits are not disease
specific, and may be extrapolated to other neurodegenera-
tive disorders – even beyond AD and A-T. Indeed, Rozas et
al. [36] have recently shown that glutamine supplementa-
tion prolongs the survival of mice with tuberous sclerosis,
an autosomal dominant neurodevelopmental disease.
Our discovery that glutamine and ATM interact to
influence blood glucose, body weight and the phosphor-
ylation of mTOR emphasizes that, beyond the DNA
damage response, ATM has deep connections with the
fundamental pathways of cellular metabolism. This
largely cytoplasmic function of ATM is increasingly rec-
ognized [30, 37–39] and applies to energy metabolism in
mitochondria as well. Indeed, A-T patients have an
unusual form of diabetes [21], and present with irregu-
larities in their glucose utilization [40]. A recent study
also revealed that adult asymptomatic relatives of A-T
patients (who would be expected to carry a single mu-
tated allele of ATM) have decreased glucose metabolism
in cerebellar vermis and hippocampus [22]. Additionally,
we note that loss of retinoblastoma (pRB) results in
reduced glucose utilization and enhanced susceptibility
to oxidative stress. Glutamine rescues these effects by
providing an alternative to glucose oxidation and enhan-
cing glutathione production [41]. The suggestion is that
the effects of glutamine on ATM-deficient neurons that
we report may share similarities with RB-deficient cells.
The findings by Rozas et. al., showing that glutamine
supplementation could prolong survival of mice with
tuberous sclerosis, take on added significance in this
Fig. 11 Supramolar glutamine supplementation partially rescued ATM activity loss induced reduction of BDNF expression. Wild type primary
neurons DIV14 were grown in medium containing 0 mM, 2 mM or 8 mM glutamine for 3 days and collected for gene expression
analysis. a Quantification of the BDNF common exon by real-time PCR. b BDNF exon 2, 3 and 4 expression levels measured by RT-PCR
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context. Tsc2 knockout mice supplemented with glutam-
ine survive 2 weeks longer than those without glutamine
supplement, a 20 % increase in lifespan [36]. TSC2 is a
potent mTOR suppressor and it is noteworthy that
ATM activates TSC2 to repress mTOR complex1 in
response to oxidative stress [30]. These observations
support our suggestion that glutamine may exert its pro-
tective effect on Atm−/− mice by modulating mTOR ac-
tivity. It is likely that part of this pathway passes through
an ATM node, but the finding of Rozas suggest that pas-
sage through a TSC2 node is also possible.
Glutamine is not itself a neurotransmitter but it serves
as an immediate precursor for glutamate and is only two
steps removed from GABA. It has been shown that
presynaptic glutamine transport is involved in the main-
tenance of excitatory synaptic currents [42], and glutam-
ine supplementation rescues the rapid synaptic GABA
depletion induced by astrogliosis, thus restoring inhibi-
tory synaptic currents in mouse CA1 neurons [25].
Given that ATM is involved in neuronal vesicle traffick-
ing [16] and its concentrations are sensitive to the avail-
ability of glutamine (Fig. 8 and reference [1]) it is
tempting to speculate that glutamine increases the small
amounts of residual ATM protein found in the Atm−/−
brain [39] thus partially restoring function.
Several additional features of the LTP experiments de-
serve mention. First, because our measurements were
made in isolated brain slices over a period of several
hours, it would appear that the effects of glutamine are
long-term in nature rather than reflecting short-term,
moment-to-moment, changes in transmitters. The re-
cording medium, in which the slices were bathed during
our measurements, contained only balanced salt solution
and no added glutamine. Therefore, the LTP differences
must represent chronic changes that remain stable even
after the extracellular environment of the synapse is
changed. Second, RT-PCR results revealed a partial res-
cue of BDNF mRNA (common exon) and almost total
restoration of exon 4 expression after glutamine supple-
mentation (8 mM) in KU-treated neurons (Fig. 11). This,
combined with the fact that glutamine’s effects on LTP
are strongest in late-LTP, which is dependent on BDNF
[32], makes it possible that glutamine acts through res-
toration of BDNF in the same way that it improves
stress-response proteins such as 53BP1, ATM, ATR, etc.
Untreated Atm−/− mice present with lower blood
glutamine concentrations suggesting that glutamine me-
tabolism may be impaired in A-T patients as well. The
expression data summarized in Fig. 7 are consistent with
this conclusion, and the independent URA analysis fur-
ther supports the importance of glutamine in the
changes in homeostasis brought on by ATM deficiency.
Examination of the pathways involved suggests that
while glutamine conversion to glutamate is likely
upregulated in A-T, the pathways leading beyond glu-
tamate are reduced (at least in brain). This would be
predicted to deplete local glutamine stores, possibly at
the expense of side pathways leading to asparagine and
glucosamine (Fig. 7). This decrease in side pathway
products could have a multitude of negative effects. For
example, decreased asparagine would be expected to be
destructive. ASNS-deficiency leads to progressive cere-
bral atrophy and intellectual disability [43] and can cause
severe neurological impairment without involvement of
peripheral tissues. Because of the poor transport of as-
paragine across the blood–brain barrier, the brain de-
pends on local synthesis, suggesting that even a small
block in its synthesis could have huge effects on brain
function [44]. Glutamine is also an important precursor
for de novo synthesis of arginine in humans [45]. Recent
studies suggest that low level of total brain arginine con-
tribute to neurodegeneration in Alzheimer’s disease [46];
a similar pathway may work in A-T brains too. De-
creased GFPT expression predicts a lower glucosamine
production in A-T brains. Glucosamine exerts a neuro-
protective effect via suppression of inflammation
through its ability to inhibit NFkB activation [47]; there-
fore, lower glucosamine would forecast higher NFkB ac-
tivity in A-T brains. Other changes predicted from the
expression array data enhance the picture further. For
example, α-ketoglutarate is a major metabolite that feeds
directly into TCA cycle and its reduction would result in
lower cellular energy. Reduced GAD can lead to reduced
GABA synthesis and decreased GABAergic transmission.
Lastly, since GSS catalyzes the final step of glutathione
production and its expression was significantly reduced
in A-T, a situation of lower glutathione production with
concomitant reduction in anti-oxidant defenses would
be predicted.
Glutamine is known to support fast growing cells in
culture and in tumor grafts [48]. Indeed tumor cells are
often described as ‘addicted’ to glutamine [49]. An oft-
cited reason for the low life expectancy of Atm−/− mice
(about 3 months in our colony) is their high cancer pre-
dilection. Almost all Atm−/− mice die of thymic lymph-
omas. Thus we initially worried that, despite its
significant neuroprotective properties, by elevating sys-
temic concentrations of glutamine to improve nervous
function we would be promoting the establishment and
growth of tumors in the Atm−/− mice. Rather than caus-
ing premature death, however, oral glutamine supple-
mentation paradoxically increased the lifespan of the
Atm−/− mice by about one-third. In fact, Atm−/− mice
supplemented with glutamine appeared to have slower
tumor progression (Fig. 6). In line with our observations
in Atm−/− mice, it has been shown that rats with carcin-
oma had significantly lower muscle glutamine content
and the size of tumor negatively correlated with the
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glutamine level [50]. Significantly lower plasma glutam-
ine level has also been reported in breast cancer patients
and in male gastrointestinal cancer patients [51]. The
implication is that glutamine’s effect on tumor growth is
context-dependent [52]. Both human and animal studies
suggest that glutamine can be given to breast cancer
patients without stimulating tumor growth or metastasis.
The reasons for this are unknown, but glutamine gener-
ally strengthens the immune system, especially the nat-
ural killer cells, and thus might boost the body’s own
defenses against cancer [53–55]. Whatever the ultimate
explanation, it would appear in the right clinical circum-
stances it is possible to take advantage of the ability of
glutamine to improve brain function yet not hasten
death due to cancer.
Conclusions
We have shown previously that glutamine is neuropro-
tective in vitro and in mouse models of AD. We have
now extended these AD-related studies to A-T. Unlike
AD, A-T is entirely a genetic disease, yet the epigenetic
landscape of the chromatin is part of the realization of
the phenotype. To the extent that the disease symptoms
result in part from these epigenetic changes, it is reason-
able to predict that environmental factors can alter the
timing and perhaps the extent of various disease events.
Our data suggest that glutamine is a powerful part of an
organism’s internal environment, and that changes in its
concentrations have a huge impact on the function of the
organism in general and the brain in particular. Glutamine
supplementation is a promising therapeutic candidate for
the treatment of human AD, A-T and beyond.
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